Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02464501 · ClinicalTrials.gov registry record · NA
The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee
A NA study of Cardiovascular Disease and Peripheral Arterial Disease, sponsored by Horizons International Peripheral Group.
- Completed
- Registry status
- NA
- Development phase
- 112
- Enrollment target
- 17
- Study locations
NCT02464501 is a NA study of Cardiovascular Disease and Peripheral Arterial Disease that has completed, run by Horizons International Peripheral Group. The registered enrollment target is 112 participants, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (96% lower). The trial reports 17 study locations across 10 states.
The verdict
NCT02464501, a NA study of Cardiovascular Disease and Peripheral Arterial Disease, has completed, sponsored by Horizons International Peripheral Group.
- COMPLETED
- Registry status
- NA
- Development phase
- 112 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of paclitaxel administration using the occlusion perfusion catheter (OPC) for the prevention of restenosis in infrainguinal de novo, restenotic femoropopliteal and infrapopliteal stenoses and occlusions, and in-stent restenosis.
Conditions Studied
Interventions
- OTHER Paclitaxel administration using the OPC
Study Locations (17)
Texas
- Huntsville Memorial Hospital - Huntsville
- North Dallas Research Associates - McKinney
- Cardiovascular Associates of East Texas - Tyler
- Tyler Cardiovascular Consultants - Tyler
Michigan
- Michigan Outpatient Vascular Institute - Dearborn
- St. John Hospital - Detroit
- Mid-Michigan Heart & Vascular Center - Saginaw
Florida
- First Coast Cardiovascular Institute - Jacksonville
- Coastal Vascular and Interventional - Pensacola
Tennessee
- University Surgical Associates - Chattanooga
- Kore Cardiovascular Research - Jackson
Alabama
- Cardiology Associates - Fairhope
Iowa
- Vascular Institute of the Midwest - Davenport
Louisiana
- Cardiovascular Institute of the South - Houma
Mississippi
- Hattiesburg Clinic - Hattiesburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2015-05-20 |
| Est. Completion | 2019-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02464501
The ClinicalTrials.gov registry entry for NCT02464501 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (96% lower). The listed sponsor is Horizons International Peripheral Group, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 1 intervention - of which Paclitaxel administration using the OPC is the first listed.
NCT02464501 reports 17 study locations spanning 10 distinct geographic areas - top geographies include Texas, Michigan, Florida.
Frequently Asked Questions
What is clinical trial NCT02464501 about?
NCT02464501 is a clinical study titled "The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee". The purpose of this study is to assess the safety and efficacy of paclitaxel administration using the occlusion perfusion catheter (OPC) for the prevention of restenosis in infrainguinal de novo, restenotic femoropopliteal and infrapopliteal stenoses and occlusions, and in-stent restenosis.
What is the current status of trial NCT02464501?
This trial is currently completed. It is a NA study. The enrollment target is 112 participants. The study started on 2015-05-20. Estimated completion is 2019-11.
What conditions does trial NCT02464501 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Peripheral Arterial Disease, Peripheral Vascular Disease.
What interventions are being tested in trial NCT02464501?
The interventions under investigation include: Paclitaxel administration using the OPC (OTHER).
Who is sponsoring clinical trial NCT02464501?
This trial is sponsored by Horizons International Peripheral Group, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02464501 being conducted?
This trial has 17 study locations across Alabama, Florida, Iowa, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
RECRUITING · NA
-
A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
RECRUITING · NA
-
Gauging Outcomes of Total Milk Ingestion on Lipid and gControl
RECRUITING · NA
-
Determining the Benefits of Exercise on Cardiovascular Risk in PTSD
RECRUITING · NA
-
Century Trial, a Randomized Lifestyle Modification Study for Management of Stable Coronary Artery Disease
ACTIVE NOT RECRUITING · NA
-
Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.